New abilities to enhance cancer research at the Australian Synchrotron

31 MARCH 2017

It gave me great pleasure to today unveil the newest research tool that Australian scientists and researchers have in the fight against cancer.

The Australian Synchrotron’s new multi-million dollar Australian Cancer Research Foundation (ACRF) Detector will fast-track new and better ways of responding to cancer, by enabling researchers to more than double their outputs and gain answers to their questions sooner.

The ACRF Detector is a great example of how collaboration between research facilities, not-for-profit organisations and government can improve outcomes for the entire Australian community.

Cancer is the leading cause of death around the globe. At the Australian Synchrotron, more than 60 per cent of all the research conducted on the Micro Crystallography (MX2) beamline is dedicated to cancer research, but that beamline was at capacity.

Installation of the ACRF Detector will more than double the beamline’s capacity to collect data.

This will mean more researchers can access this state-of-the-art infrastructure, leading to more targeted and effective treatments, improving care and outcomes for patients.

This investment in Australian research and technology has the potential to increase the rate at which research turns into practical applications for patients and the community, helping us find answers to important questions in cancer and medical research sooner than is currently possible.

High quality research, collaboration and smart investment are needed to ensure that research and knowledge are supported – I am thrilled to be witness to that today with the official reveal of the ACRF detector.

The Australian Synchrotron is owned by the Australian Nuclear Science and Technology Organisation (ANSTO).